Shares of Johnson & Johnson JNJ slipped 0.01% to $154.52 Tuesday, on what proved to be an all-around positive trading session ...

The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities that receive the discounts from drug manufacturers.